Bayer Secures FDA Approval for Hemophilia A Treatment, Jivi

Hemophilia A patients have another treatment option. This morning the U.S. Food and Drug Administration (FDA) gave the nod to Bayer AG’s new treatment, Jivi (BAY94-9027). The newly approved Jivi is intended for use as a routine prophylactic treatment in adult patients who previously underwent treatment for hemophilia A. One of the benefits of Jivi, according to Bayer, is the … Συνεχίστε να διαβάζετε Bayer Secures FDA Approval for Hemophilia A Treatment, Jivi.